Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
Wachstum
Das Unternehmen befindet sich in einer Wachstumsphase, wobei das aktuelle Jahreseinkommen insgesamt 32.00K USD beträgt.
Hohe Gewinnwachstumsrate
Das Nettoeinkommen des Unternehmens führt die Branche an, das letzte Jahres Einkommen betrug insgesamt 32.00K USD.
Unterbewertet
Die aktuelle PE1 des Unternehmens liegt bei -1.622, im niedrigen 3-Jahres-Perzentilbereich.
Institutionelle Käufe
Die neuesten institutionellen Bestände sind 2.77M Aktien, was eine Steigerung von 42.98% im Vergleich zum Vorquartal darstellt.